更新于：2024-07-01

Niclosamide

氯硝柳胺

更新于：2024-07-01

概要

概要

基本信息

药物类型

小分子化药

别名

FW-CD、FW-COV、FW-ICI-AC

+ [24]

靶点

AR-v7

作用机制

AR-v7抑制剂(雄激素受体剪接变异体7抑制剂)、线粒体氧化磷酸化解偶联剂

治疗领域

感染呼吸系统疾病消化系统疾病+ [1]

在研适应症

新型冠状病毒感染直肠结肠炎溃疡性直肠炎+ [3]

非在研适应症

蛔虫病糖尿病肾病

原研机构

Bayer Pharmaceuticals Corp.

在研机构

Entero Therapeutics, Inc.

First Wave Bio, Inc.

TFF Pharmaceuticals, Inc.

+ [4]

非在研机构

Bayer AG

Daewoong Pharmaceutical Co., Ltd.

Tanta University

+ [1]

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C13H10Cl2N2O5

InChIKeyZBXRPLQCPHTHLM-UHFFFAOYSA-N

CAS号73360-56-2

关联

项与氯硝柳胺相关的临床试验

NCT05188170 / Recruiting临床1期IIT

Phase 1 Study of Niclosamide (ANA001) in Pediatric Patients With Relapsed and Refractory AML

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

开始日期2022-11-21

申办/合作机构

Stanford University

KCT0007307 / Completed临床2期

A randomized, double-blind, placebo-controlled design phase 2 clinical trial to comparatively evaluate the efficacy and safety of CP-COV03 in patients with mild or moderate COVID-19

开始日期2022-05-11

申办/合作机构

HYUNDAI BIOSCIENCE Co., Ltd.

NCT05226533 / Terminated临床2期

A Phase 2, Double Blind, Randomized, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of DWRX2003 in Combination With Remdesivir Following Intramuscular Administration in Moderate-Severe COVID-19 Patients

Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.

开始日期2022-03-31

申办/合作机构

Daewoong Pharmaceutical Co., Ltd.

100 项与氯硝柳胺相关的临床结果

登录后查看更多信息

100 项与氯硝柳胺相关的转化医学

登录后查看更多信息

100 项与氯硝柳胺相关的专利（医药）

登录后查看更多信息

1,108

项与氯硝柳胺相关的文献（医药）

2106-07-05·Oncotarget

Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling

Article

作者: Zhang, Junxiang ; Zhang, Yaping ; Yin, Lina ; Zhang, Xuxia ; Wang, Jing ; Gao, Yun ; Chen, Honghong ; Ding, Defang

Triple-negative breast cancer (TNBC) is one of the most difficult breast cancers to treat because there is no targeted treatment, and conventional cytotoxic chemotherapy followed by adjuvant radiation therapy is the standard of care for patients with TNBC. We herein reported that ionizing radiation (IR) induced Wnt3a, LRP6 and β-catenin expression and consequently activated Wnt/β-catenin signaling in TNBC MDA-MB-231, MDA-MB-468 and Hs578T cells. Moreover, depletion of β-catenin by shRNA sensitized TNBC cells to IR, whereas treatment of Wnt3a protein or overexpression of β-catenin resulted in radioresistance of TNBC cells. Niclosamide, a potent inhibitor of Wnt/β-catenin signaling, not only inhibited constitutive Wnt/β-catenin signaling, but also blocked IR-induced Wnt/β-catenin signaling in TNBC cells. In addition, niclosamide sensitized TNBC cells to IR, prevented Wnt3a-induced radioresistance, and overcame β-catenin-induced radioresistance in TNBC cells. Importantly, animals treated with the combination of niclosamide and γ-ray local tumor irradiation had significant inhibition of MDA-MB-231 tumor growth compared with treated with local tumor irradiation alone. These findings indicate that Wnt/β-catenin signaling pathway plays an important role in the development of radioresistance of TNBC cells, and that niclosamide had significant radiosensitizing effects by inhibiting Wnt/β-catenin signaling in TNBC cells. Our study also provides rationale for further preclinical and clinical evaluation of niclosamide in TNBC management.

2024-02-01·Toxicology and applied pharmacology

Chemical mixture that targets the epidermal growth factor pathway impairs human trophoblast cell functions

Article

作者: Ticiani, Elvis ; Waye, Anita A ; Veiga-Lopez, Almudena

Pregnant women are exposed to complex chemical mixtures, many of which reach the placenta. Some of these chemicals interfere with epidermal growth factor receptor (EGFR) activation, a receptor tyrosine kinase that modulates several placenta cell functions. We hypothesized that a mixture of chemicals (Chem-Mix) known to reduce EGFR activation (polychlorinated biphenyl (PCB)-126, PCB-153, atrazine, trans-nonachlor, niclosamide, and bisphenol S) would interfere with EGFR-mediated trophoblast cell functions. To test this, we determined the chemicals' EGFR binding ability, EGFR and downstream effectors activation, and trophoblast functions (proliferation, invasion, and endovascular differentiation) known to be regulated by EGFR in extravillous trophoblasts (EVTs). The Chem-Mix competed with EGF for EGFR binding, however only PCB-153, niclosamide, trans-nonachlor, and BPS competed for binding as single chemicals. The effects of the Chem-Mix on EGFR phosphorylation were tested by exposing the placental EVT cell line, HTR-8/SVneo to control (0.1% DMSO), Chem-Mix (1, 10, or 100 ng/ml), EGF (30 ng/ml), or Chem-Mix + EGF. The Chem-Mix - but not the individual chemicals - reduced EGF-mediated EGFR phosphorylation in a dose dependent manner, while no effect was observed in its downstream effectors (AKT and STAT3). None of the individual chemicals affected EVT cell invasion, but the Chem-Mix reduced EVT cell invasion independent of EGF. In support of previous studies that have explored chemicals targeting a specific pathway (estrogen/androgen receptor), current findings indicate that exposure to a chemical mixture that targets the EGFR pathway can result in a greater impact compared to individual chemicals in the context of placental cell functions.

2024-02-01·The Science of the total environment

Effects of environmentally relevant concentrations of niclosamide on lipid metabolism and steroid hormone synthesis in adult female zebrafish

Article

作者: Zhou, Bingsheng ; Yang, Lihua ; Han, Jian ; Chen, Xianglin ; Zhu, Biran ; Yang, Shangyue ; Zhang, Mengyuan ; Li, Ruiwen ; Hua, Jianghuan ; Zheng, Na

Niclosamide (NIC) is a commonly used molluscicide that reportedly disrupts the endocrine system and may lead to lipid metabolism disorders. However, few studies have investigated the mechanism by which NIC affects the endocrine system from the perspective of lipid metabolism. Adult female zebrafish were fed either a normal-fat diet (NFD) or a high-fat diet (HFD) and then exposed for 28 days to environmentally relevant concentrations of NIC. NIC accumulated most in the liver followed by the brain and then the gonads in both feeding conditions. Somatic index changes confirmed that HFD promotes fish growth, and NIC administration inhibits it. Lipid metabolites were decreased by NIC, as were levels of pregnenolone, androstenedione, estrogen, testosterone, and estradiol, suggesting that NIC impacted steroidogenesis. In addition, gene transcription changes related to the hypothalamic-pituitary-gonad-liver (HPGL) axis and altered ovarian histology strongly suggest that environmental relevant concentrations of NIC exposure may disrupt endocrine function. These findings highlighted that NIC exposure at environmentally relevant concentrations elicited endocrine-disruption effects may through impairing of steroid hormone synthesis.

142

项与氯硝柳胺相关的新闻（医药）

2024-06-27

·Science Daily

Intriguing new tool for tendon healing: nanoparticles for precision drug delivery

Harnessing nanoparticles to deliver drugs precisely to a surgically repaired tendon is a promising new approach that reduced scar tissue formation and improved mechanical function. Harnessing nanoparticles to deliver drugs precisely to a surgically repaired tendon is a promising new approach that reduced scar tissue formation and improved mechanical function in a study appearing in Science Advances. Researchers' success in pinpointing a drug therapy inside the body, at the cellular level, proved to be a highly efficient delivery method that could be used to treat other injuries. Whether it's a season-ending Achilles rupture by pro footballer Aaron Rodgers or an everyday workplace accident, tendon injuries are common and can be life-changing. They require 300,000 surgeries per year and often result in lost work time and permanent impaired physical function. Typically, traumatic tendon injuries are surgically repaired with sutures, but optimal healing is often impaired by the tendon's propensity to heal with scar tissue that restricts tendon movement and function. Researchers at the University of Rochester and University of Oregon combined their expertise in tendon cell biology and drug delivery systems to find a better way to deliver therapies that can reduce scar tissue and facilitate improved healing. "There are very few effective drug regimens to assist the tendon healing process, despite the high number of these injuries and the poor outcomes that often result," said Alayna Loiselle, PhD, associate professor at the University of Rochester's Center for Musculoskeletal Research. "Systemic drug treatments delivered orally or via injection show poor tendon homing; in some cases, less than 1 percent of a systemically delivered medication reaches the healing tendon. Local administration of drugs directly to the tendon has disadvantages as well, including potential tissue damage from the injection and poor control over drug concentrations at the point of injury." "We want to pivot from using suturing alone to incorporating therapeutics," said Emmanuela Adjei-Sowah, a Biomedical Engineering PhD student at the University of Rochester, who has spent the past several years working with co-authors Loiselle, Danielle S.W. Benoit, PhD, and others to develop the nanoparticle delivery system to improve healing in tendon injuries. "Advances in multiomics and drug delivery using nanoparticles open up new possibilities in treatment." The challenge for researchers was to identify which substances could assist tendon healing. Molecular 'map' of healing process charts a new therapeutic path "The fundamental cellular and molecular mechanisms that drive scar-mediated tendon healing are really only just beginning to be well-defined," Loiselle said. "Our prior work used spatial transcriptomic profiling to define a molecular map of the healing tendon. In subsequent analysis of this data, we found that the area right at the injury site had high levels of Acp5 gene expression, which was both surprising and exciting." The Acp5 gene produces a protein called Tartrate Resistant Acid Phosphatase (TRAP); both are known to occur as injured bones recover and rebuild. High TRAP activity within the healing tendon allowed researchers to employ a peptide that binds with TRAP to deliver medication directly to the healing tendon site. "While Benoit's lab has previously used TRAP-binding peptide nanoparticles (TBP-NP) for targeted drug delivery to bone, high TRAP activity in the healing tendon opened up an entirely new research direction," Loiselle said. Prior to initiating studies with therapeutic agents, the team completed a series of dose and timing studies, using a mouse model of complete transection and surgical repair of the flexor tendon, to define the window in which their drug delivery system could most effectively target the healing tendon. "Defining an optimal treatment window is critical to successfully developing an innovative and effective drug delivery system that improves tendon healing by encouraging a more regenerative, rather than fibrotic, healing cascade," said Benoit, the Lorry Lokey Department Chair and Professor in the Department of Bioengineering at the University of Oregon. "In addition, by defining the optimal therapeutic window for this drug delivery system, we can mitigate the unwanted side effects that typically accompany the high doses or multiple doses required to achieve sufficient drug accumulation in the tissue." As a therapeutic, the team chose Niclosamide, which inhibits S100a4, a protein that Loiselle's lab already identified as contributing to scar formation. Previous work from Loiselle's lab demonstrated that genetic knockdown of S100a4 improved mechanical and functional outcomes in this mouse tendon healing model. S100a4 has been implicated in scar formation in many tissues, including the liver, heart, lung, and oral submucosa; Loiselle's discovery that it complicates tendon healing gave them a therapeutic target for this study, where they used their TRAP-binding peptide nanoparticle drug delivery system to precisely affect the injured tendon. As a comparison, they delivered Niclosamide systemically; it did slightly reduce the amount of S100a4 in the healing tendon but it had no beneficial impact on the healing process. In contrast, delivery of the same dose of Niclosamide using the nanoparticle system resulted in robust inhibition of S100a4 mRNA and protein levels in the healing tendon. This targeted drug delivery method also significantly benefited the tendon healing process. TBP-NP delivery of Niclosamide improved both functional range of motion recovery and increased the mechanical integrity of the healing tendon across both short- and longer-term timepoints. Importantly, these sustained effects occurred with just a single treatment. Researchers will continue their work to define how broadly the system can be used for other tendon injuries and disease, as well as other types of tissue injury that result in scar formation. "The beauty of this system is that it can be loaded with different kinds of drugs to target different molecular processes or pathways," said Adjei-Sowah.

2024-06-26

·PRNewswire

Hyundai Bioscience succeeds in developing 'Multi-treatment for mosquito-borne viral infections' including Dengue Fever

Developed a 'Niclosamide-based multi-treatment drug' that can simultaneously treat mosquito-borne viral infections such as four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever. Accelerating preparations for dengue fever basket clinical trial scheduled to be conducted in Brazil. SEOUL, South Korea, June 25, 2024 /PRNewswire/ -- Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a 'multi-treatment drug for mosquito-borne viral infections, including dengue fever,' using niclosamide as the main ingredient. This treatment, which contains niclosamide as the main active pharmaceutical ingredient, can maintain a blood niclosamide concentration (IC50) to inhibit the proliferation of viruses such as the four serotypes of dengue virus, Zika, Chikungunya, and Yellow Fever, by 50%. To effectively treat dengue fever, the antiviral must be administered early, before the viral load increases significantly. For early administration, the treatment must be effective not only against dengue fever but also against other mosquito-borne viral diseases with similar symptoms, such as Zika, Chikungunya, and Yellow Fever. Leveraging its patented technology, Hyundai Bioscience has enhanced the bioavailability of niclosamide, enabling it to treat arbovirus infections caused by Zika, Chikungunya, and Yellow Fever viruses in addition to dengue fever. Recently, the company has succeeded in developing a "niclosamide-based multi-treatment for mosquito-borne viral infections" that can maintain an IC50 in the blood to inhibit the replication of these viruses. Currently, there is no treatment for dengue fever. The dengue virus has four serotypes (DENV-1, DENV-2, DENV-3, DENV-4), each with different IC50 values. The IC50 values for Zika, Chikungunya, and Yellow Fever viruses, which are also mosquito-borne, vary as well. Hyundai Bioscience's multi-treatment drug candidate is the world's first to maintain niclosamide's blood concentration above the IC50 value of all four serotypes of dengue virus as well as Zika, Chikungunya, and Yellow Fever viruses. Hyundai Bioscience has formulated the multi-treatment antiviral into a tablet form to facilitate mass production and to make it convenient for transportation and storage. Hyundai Bioscience has decided to conduct the dengue fever basket clinical trial in Brazil, the country most affected by dengue fever. Hyundai Bioscience USA will soon select a Contract Research Organization (CRO). The dengue fever clinical trial, to be conducted by Hyundai Bioscience USA in Brazil, will use a basket clinical trial approach, differing from traditional clinical trial methods. This involves early administration of the multi-target antiviral to patients infected with mosquito-borne viruses, including the four serotypes of dengue virus, Zika, and Chikungunya, followed by evaluating the clinical efficacy in patients with confirmed dengue virus. Kim Kyung-il, CEO of Hyundai Bioscience USA, stated, "With the development of a multi-treatment drug candidate capable of simultaneously treating various mosquito-borne viral infections such as dengue fever, we plan to conduct the basket clinical trial in Brazil as soon as possible. Through expedited regulatory processes in Brazil, we aim to supply the treatment at an affordable price to patients suffering from dengue fever worldwide." About Hyundai Bioscience Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea. For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]). SOURCE Hyundai Bioscience

临床研究

2024-06-26

·BioSpace

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities. “We are pleased to announce this engagement with Outcome Capital, which is a well-recognized investment bank specializing in corporate advisory services to the life sciences industry,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. “Today’s announcement reflects the significant innovation and commercial potential of our two lead clinical assets, TFF VORI and TFF TAC, and we welcome the opportunity to work with Outcome Capital in evaluating select partnering or licensing opportunities that can bring significant value to our shareholders.” “In recent months, TFF Pharmaceuticals has made extraordinary progress in demonstrating how its leading formulation technology can be applied to generate innovative clinical-stage products with the potential to improve upon the current standard of care,” said Oded Ben-Joseph, Ph.D., MBA, Managing Partner of Outcome Capital. “We look forward to identifying and evaluating opportunities to realize the full potential value of TFF Pharmaceutical’s exciting Phase 2 assets.” About TFF TAC TFF TAC is an inhaled dry powder formulation of tacrolimus, a potent immunosuppressive drug. Oral tacrolimus is currently the first line calcineurin inhibitor used for prevention of rejection after solid organ transplantation but it is associated with many toxicities such as kidney toxicity, particularly when high doses are needed as is the case after lung transplantation TFF TAC delivers tacrolimus directly to the lung to yield improved lung immunosuppression at lower doses and systemic exposures compared to oral tacrolimus to improve efficacy and decrease systemic toxicities such as kidney toxicity. TFF TAC is delivered via an easy-to-use dry powder inhaler. The ongoing Phase 2 trial of TFF TAC is an open-label study in lung transplant patients who require reduced tacrolimus blood levels due to kidney toxicity. Part A of the trial is a 12-week treatment period, and Part B is an optional safety extension period. Trial endpoints include safety and tolerability including kidney function, acute allograft rejection and pharmacokinetics. ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING (TFF) TECHNOLOGY TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by TFF can deliver as much as 75% of the dose to the deep lung. TFF does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of TFF can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products. ABOUT TFF PHARMACEUTICALS TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile TFF technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation or for topical delivery to the eyes, nose and skin. SAFE HARBOR This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the innovation and commercial potential of the Company’s TFF VORI and TFF TAC product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including (i) the risk that the Company may not realize the innovation and commercial potential of TFF VORI and TFF TAC through its collaboration with Outcome Capital or otherwise, (ii) success in early phases of pre-clinical and clinical trials do not ensure later clinical trials will be successful; (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 14, 2024. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. InvestorRelationsContact: Corey Davis, Ph.D. LifeSci Advisors (212) 915-2577 cdavis@lifesciadvisors.com

临床2期

100 项与氯硝柳胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00436	氯硝柳胺	P02DA01	DB06803

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
蛔虫病	美国	Bayer Pharmaceuticals Corp.	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	美国	NeuroBo Pharmaceuticals, Inc.	2020-10-07
糖尿病肾病	临床3期	埃及	Tanta University	2020-02-01
胃肠道感染	临床2期	美国	Entero Therapeutics, Inc.	2021-04-30
胃肠道感染	临床2期	印度	Entero Therapeutics, Inc.	2021-04-30
胃肠道感染	临床2期	乌克兰	Entero Therapeutics, Inc.	2021-04-30
直肠结肠炎	临床2期	意大利	Entero Therapeutics, Inc.	2018-05-15
溃疡性直肠炎	临床2期	意大利	Entero Therapeutics, Inc.	2018-05-15
克罗恩病	临床1期	-	First Wave Bio, Inc.	-
腹泻	临床前	美国	First Wave Bio, Inc.	2022-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04317430 (Literature) 人工标引	临床3期	糖尿病肾病	60	niclosamide+ramipril	製齋膚範簾壓憲積選廠(鹹憲醖膚淵繭醖顧鹽觸) = 壓窪觸襯積醖糧鬱憲獵鑰顧壓膚膚醖顧簾鏇願 (繭淵廠窪膚憲餘餘繭願, -30to-18.3) 更多	积极	2023-02-16
NCT04317430 (Literature) 人工标引	临床3期	糖尿病肾病	60	ramipril	製齋膚範簾壓憲積選廠(鹹憲醖膚淵繭醖顧鹽觸) = 夢衊壓壓範獵鹹鹹艱淵鑰顧壓膚膚醖顧簾鏇願 (繭淵廠窪膚憲餘餘繭願, 4to18.2) 更多	积极	2023-02-16
NCT04399356 (Pubmed) 人工标引	临床2期	新型冠状病毒感染	73	Niclosamide	遞觸壓鏇顧構願積齋鏇(網憲醖鬱顧襯衊膚鏇糧) = 築選廠顧糧鏇繭艱鏇積範艱網餘齋觸選繭積齋 (壓鬱鬱夢顧製醖鑰選構, 50.74 ~ 81.81) 更多	不佳	2022-02-01
NCT04399356 (Pubmed) 人工标引	临床2期	新型冠状病毒感染	73	Placebo	遞觸壓鏇顧構願積齋鏇(網憲醖鬱顧襯衊膚鏇糧) = 淵壓網窪選遞築鏇夢糧範艱網餘齋觸選繭積齋 (壓鬱鬱夢顧製醖鑰選構, 40.27 ~ 72.73) 更多	不佳	2022-02-01
NCT02807805 (ASCO2018)	临床2期	去势抵抗性前列腺癌	6	Niclosamide/PDMX1001 + Abiraterone + Prednisone	襯衊鏇鑰壓網觸鑰鑰壓(膚觸製積齋觸簾築鬱膚) = two with partial PSA response (≥50% decrease) 餘齋襯淵簾窪齋膚餘願 (製網廠衊蓋壓選夢醖蓋 ) 更多	积极	2018-06-01
ASN2016	N/A	再灌注损伤	-	Niclosamide	簾簾醖網淵遞積糧壓淵(艱構鹽襯壓廠遞網鏇繭) = I/R-induced fatty acid deposition in tubular epithelium was almost diminished in niclosamide-treated mice 獵願範膚繭襯選淵鏇構 (遞鹹鏇餘繭範淵構衊糧 ) 更多	积极	2016-11-15